HKHarbir Singh Kohli

Harbir Singh Kohli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Harbir Singh Kohli has a total of 339 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Randomized Controlled Trial Comparing Lactoferrin+Iron with Iron Alone for Iron Deficiency Anemia in CKD

    by Smita Divyaveer, Kushal Kekan, Madhuri Kashyap, Maninder Kaur, Kanchan Prajapati, Madhumita Premkumar, Deepy Zohmangaihi, Nabhajit Mallik, Deepesh Lad, Ravjit Singh Jassal, et al.

    Key Points: Lactoferrin+iron significantly improved hemoglobin and iron indices versus iron alone in CKD patients with iron deficiency anemia. Lactoferrin reduced hepcidin and inflammatory markers, suggesting improved iron utilization using anti-inflammatory mechanisms. Three patients with iron deficiency anemia had elevated inflammatory markers, higher among patients with CKD on dialysis than those not on dialysis. Background: Lactoferrin, a multifunctional iron-binding glycoprotein with anti-inflammatory properties, is reported to be effective in anemia in pregnant women and patients with malignancy but has not been tested elaborately in CKD. Methods: In this randomized, open-label trial, 185 patients (intention-to-treat) with iron-deficiency anemia (hemoglobin [Hb] <10 g/dl, transferrin saturation <20%) were enrolled: 90 with patients with CKD not on dialysis (CKD-ND) and 95 with dialysis-dependent CKD (patients with CKD on dialysis [CKD-5D]). Patients were randomized to receive either oral iron (30 mg/d liposomal iron) or oral iron+lactoferrin (100 mg twice daily) for 3 months. The primary outcome was change in Hb. Secondary outcomes included iron indices and inflammatory markers (C-reactive protein, IL-6, erythrocyte sedimentation rate, and hepcidin). Results: In the intention-to-treat analysis, lactoferrin+iron resulted in significantly greater improvements in Hb and iron parameters than iron alone in both patients with CKD-ND and those with CKD-5D. Mean Hb increased by 1.95±1.19 versus 1.33±0.86 g/dl in patients with CKD-ND and by 1.73±0.96 versus 1.11±0.93 g/dl in patients with CKD-5D receiving lactoferrin+iron and iron alone, respectively. Improvements in iron indices were also greater with add-on lactoferrin treatment. Mean difference in hepcidin levels were −20.24±15.99 versus −16.03±40.65 ng/dl in patients with CKD-ND and −15.29±8.73 versus −20.99±20.16 ng/dl in patients with CKD-5D treated with lactoferrin+iron and iron alone, respectively. Conclusions: Among patients with CKD-associated anemia, adjunctive lactoferrin therapy improved Hb and iron parameters compared with oral iron alone in both non–dialysis-dependent and dialysis-dependent patients. Lactoferrin was also associated with modest improvements in inflammatory status, although effects on individual inflammatory markers were inconsistent. These findings suggest that lactoferrin may be a useful adjunct to oral iron therapy for the management of anemia in CKD, especially in resource-limited settings. Clinical Trial registry name and registration number: Clinical Trials Registry of India, CTRI/2020/04/024746.

  • Augmented mannose‐binding lectin levels in primary membranous nephropathy: A pilot study

    by Deeksha Pal, Neeraj Inamdar, Prabhjot Kaur, Manphool Singhal, Anupam Lal, Ujjwal Gorsi, Ritambhra Nada, Harbir S. Kohli, Vinod Kumar, Raja Ramachandran

    There is evidence to suggest that M‐type phospholipase A2 (PLA2R) antibodies activate the mannose‐binding lectin (MBL) cascade, resulting in glomerular damage and proteinuria in patients with primary membranous nephropathy (PMN). Furthermore, there are few reports indicating that aberrant MBL activation is associated with endothelial dysfunction and accelerated atherosclerosis. While PMN is a common cause of adult nephrotic syndrome, and patients are at increased risk of cardiovascular disease (CVD), there is a lack of research that explores the factors that contribute to this condition. This study aims to determine the MBL levels in PMN and their relation to the clinical activity and endothelial dysfunction in PMN. The MBL levels of 22 biopsy‐confirmed PMN patients were assessed at baseline and after 6 months of immunosuppressive therapy. In order to evaluate endothelial dysfunction in PMN patients, flow‐mediated vasodilation (FMD) was measured at baseline and after treatment. A total of 22 healthy controls were included in this study to measure MBL levels and FMD. A significant difference was observed between MBL levels in PMN patients and healthy controls (p < .01). MBL levels decreased significantly after immunosuppressive therapy (p = .04). The baseline MBL levels and FMD levels exhibited a strong correlation (Spearman correlation coefficient [ρ] = 0.51: p = .01). In conclusion, the study signals the activation of the MBL cascade and its association with endothelial dysfunction in PMN patients.

  • Long-term complications in patients with childhood-onset nephrotic syndrome

    by Joyita Bharati, Karalanglin Tiewsoh, Lesa Dawman, Tarvinder Singh, Ujjwal Gorsi, Arun Prabhahar Rajarajen, Aakanksha Sharma, Rahul Chanchlani, Raja Ramachandran, Harbir Singh Kohli

    Background Reports on long-term complications of childhood-onset nephrotic syndrome (NS), such as obesity, osteoporosis, growth failure, and hypertension, are mostly from developed countries not representing South Asian ethnicities. Furthermore, data on cardiovascular health among patients with childhood-onset NS are limited. Methods This was an observational study involving patients attending a tertiary care center. Patients aged 15 years and older were examined for long-term complications and remission of NS at their visit in December 2021. Childhood-onset NS meant onset of NS before 10 years of age. Long-term complications included obesity, growth failure, low bone mineral density (BMD) Z score, hypertension, and increased carotid intima-media thickness (cIMT). Long-term remission was defined as no relapse for the last \(\ge\) 3 consecutive years without immunosuppressive medication to maintain remission. Results Of 101 patients studied (~ 80% with frequent relapsing (FR)/steroid-dependent (SD) NS), the mean age was 17.6 (± 2.4) years at the time of study. Long-term complications were noted in 89.1% of patients which included one or more of the following: obesity (22.7%), growth failure (31.7%), low BMD Z score (53.5%), hypertension (31.7%), and high cIMT (50.5%). Thirty-nine patients (38.6%) were in long-term remission at the time of the study. Growth failure and low BMD Z scores were less frequent in patients with long-term remission compared to those without long-term remission. Conclusions In patients with childhood-onset NS (predominantly FR/SDNS) who were studied at \(\ge\) 15 years of age, ~ 90% had long-term complications which included high cIMT in 50%. Only ~ 40% were in long-term remission. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Visceral infarction in Systemic lupus erythematosus mimicking medium vessel vasculitis

    by Aakanksha Sharma, Jasmine Sethi, Raghav Gupta, Sandeep Kumar Sanyasi, Harbir Singh Kohli

  • Open Access

    A structured telemedicine model in the management of COVID-19 infected kidney transplant patients in a tertiary care center in India

    by Harbir S Kohli, Tom Kakkanattu, Joyita Bharati, Raja Ramachandran

    Official peer-reviewed open access publication Indian Association of Medical Microbiologists

  • ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review

    by Arun Prabhahar, G. S. R. S. N. K. Naidu, Prabhat Chauhan, Aravind Sekar, Aman Sharma, Alok Sharma, Asheesh Kumar, Ritambhra Nada, Manish Rathi, Harbir Singh Kohli, et al.

    For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.


  • Open Access

    Impact of COVID-19 pandemic on nephrology training in an academic center in India: Looking forward through online teaching

    by HarbirSingh Kohli, Joyita Bharati

    J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society

  • Open Access

    Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens

    by Raja Ramachandran, Saurabh Nayak, Vinod Kumar, Jasmine Sethi, Ranjana Minz, Vivek Kumar, Manish Rathi, Harbir Singh Kohli

    Primary membranous nephropathy (PMN) is the most common cause of adult-onset nephrotic syndrome worldwide [ 1]. Recently, promising results of two randomized trials [ 2, 3] and a few observational studies propounded the use of rituximab as the primary therapy in anti-proteinuric refractory PMN. Authors worldwide administer varying dosage schedules of rituximab in the management of PMN with reasonable success. Into the bargain of efficacy, the cost of rituximab needs to be reckoned with, and a higher dose is extortionate. The economic implication of the therapy needs factoring, especially in a limited-resource setting. In light of these facts, we partook an analysis of three dosing regimens of rituximab therapy viz 375 mg/m2 weekly for 4 weeks (Regimen 1), 1 g on Days 0 and 15 (patients who did not achieve any clinical remission at Month 3 and had a cluster of differentiation (CD19) count of >1% or >5 cells/µL received augmented dosing of rituximab) and CD19-guided rituximab therapy, where patients underwent testing for CD19 at the third to the fourth month of rituximab infusion (375 mg/m2) (Regimen 2), and additional rituximab infusion only if CD19 count of >1% or >5 cells/µL (Regimen 3) (details given in the Supplementary file ).